Source: Wellteq
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Wellteq Digital Health (WTEQ) has signed an arrangement agreement with Advanced Human Imaging Ltd. (ASX: AHI)
  • Wellteq shareholders will receive one ordinary share of AHI for every six Wellteq common shares
  • AHI has agreed to advance up to A$1,200,000 to Wellteq
  • AHI is a provider of smartphone-based human scanning technology
  • Wellteq is a leading global provider of personalized digital health and wellness solutions
  • Wellteq Digital Health Inc (WTEQ) opened trading at C$0.02

Wellteq Digital Health (WTEQ) has signed an arrangement agreement with Advanced Human Imaging Ltd. (ASX:AHI).

Under the terms of the agreement, AHI will acquire all of the outstanding shares of Wellteq. Wellteq shareholders will receive one ordinary share of AHI for every six Wellteq common shares.

AHI will issue a total of approximately 17,811,508 shares for 100 per cent of Wellteq’s issued shares.

AHI has agreed to advance up to A$1,200,000 to Wellteq. The loan will be advanced in tranches not exceeding A$200,000. Amounts advanced under the loan will be due in six months and will bear interest at a rate of 10 per cent per annum.

AHI is a provider of smartphone-based human scanning technology, with a diverse range of data-driven applications in fitness, mHealth, life & health Insurance, and apparel.

Wellteq is a leading global provider of personalized digital health and wellness solutions. 

Wellteq Digital Health Inc (WTEQ) opened trading at C$0.02.


More From The Market Herald

This stock is ready to capture the lead in the diabetes market

Diabetes specialist Glucotrack (NASDAQ:GCTK) has changed its business strategy to transition to continuous glucose monitoring.

Ceapro starts studies of flagship product for inflammation

Ceapro (TSXV:CZO) has launched a Phase 1 study evaluating its flagship product avenanthramides in managing inflammation-related conditions.

Pharmaceutical microcap penny stock is up big after asset sale

Microcap penny stock Algernon Pharmaceuticals (CSE:AGN) has signed a letter of intent to sell its chronic cough research program to Seyltx.